Medicine and Dentistry
Chronic Kidney Disease
67%
Maturity Onset Diabetes of the Young
54%
Cardiovascular System
50%
Albuminuria
48%
Glomerular Filtration Rate
44%
Nephropathy
42%
Creatinine
33%
Diabetes
33%
Canagliflozin
33%
Patient with Type 2 Diabetes
32%
Placebo
30%
Diabetic Nephropathy
29%
Urinary System
27%
Clinical Trial
24%
Dapagliflozin
24%
Kidney Function
24%
Sodium Glucose Cotransporter 2 Inhibitor
24%
Heart Failure
20%
Biological Marker
18%
End Stage Renal Disease
18%
Post-Hoc Analysis
18%
Renal Failure
17%
Cardiovascular Disease
16%
Meta-Analysis
15%
Diabetes Mellitus
14%
Disease Exacerbation
13%
Hazard Ratio
13%
Blood Pressure
11%
Renin Angiotensin Aldosterone System
10%
Cardiovascular Risk
9%
Proteinuria
9%
Randomized Controlled Trial
9%
Microalbuminuria
8%
Treatment Effect
8%
Hemoglobin A1c
8%
Disease
7%
Sodium Intake
7%
Systolic Blood Pressure
6%
Renal Protection
6%
Adverse Outcome
6%
Empagliflozin
6%
Sodium Glucose Cotransporter 2
5%
Adverse Event
5%
Angiotensin Receptor Antagonist
5%
Proportional Hazards Model
5%
Patient with Diabetes
5%
Population
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Chronic Kidney Failure
76%
Albuminuria
60%
Dapagliflozin
55%
Creatinine
50%
Placebo
47%
Kidney Disease
45%
Diabetic Nephropathy
34%
Canagliflozin
34%
Sodium Glucose Cotransporter 2 Inhibitor
33%
Clinical Trial
32%
Heart Failure
25%
End Stage Renal Disease
20%
Kidney Failure
19%
Biological Marker
17%
Atrasentan
14%
Cardiovascular Disease
14%
Diabetes Mellitus
14%
Renin
13%
Disease Exacerbation
13%
Angiotensin Receptor Antagonist
12%
Angiotensin
11%
Randomized Controlled Trial
11%
Cardiovascular Risk
10%
Hemoglobin A1c
10%
Empagliflozin
10%
Adverse Outcome
10%
Disease
9%
Aldosterone
8%
Microalbuminuria
8%
Adverse Event
7%
Endothelin Receptor Antagonist
7%
Losartan
7%
All Cause Mortality
7%
Proteinuria
6%
Randomized Clinical Trial
6%
Brain Natriuretic Peptide
6%
Irbesartan
5%
Sodium Glucose Cotransporter 2
5%
Exendin 4
5%
Glucagon Like Peptide 1 Receptor Agonist
5%
Keyphrases
Chronic Kidney Disease
54%
Albuminuria
41%
Type 2 Diabetic Patients
40%
Type 2 Diabetes Mellitus (T2DM)
38%
Dapagliflozin
38%
Albumin-to-creatinine Ratio
29%
Canagliflozin
27%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
26%
Estimated Glomerular Filtration Rate
26%
Diabetic Kidney Disease
24%
Placebo
20%
Cardiovascular Outcomes
17%
Kidney Outcomes
14%
Confidence Interval
14%
Diabetes
14%
Hazard Ratio
12%
Nephropathy
12%
Clinical Trials
11%
Kidney Failure
11%
Kidney
10%
Renal Outcome
10%
Meta-analysis
10%
Renal Events
10%
Credence
10%
Kidney Disease Progression
9%
Adverse Outcomes
8%
Cardiovascular Mortality
8%
Kidney Function
8%
Atrasentan
8%
Risk Markers
8%
Diabetic Nephropathy
8%
Randomized Controlled Trial
7%
Clinical Evaluation
7%
Heart Failure
7%
Urinary Albumin Excretion
6%
Angiotensin Receptor Blockers
6%
Patients with Diabetes
6%
Proteinuria
6%
Kidney Disease
6%
Treatment Effect
6%
Multiple Risk Factors
5%
Blood Pressure
5%
Estimated Glomerular Filtration Rate Decline
5%
Microalbuminuria
5%
Cardiovascular Events
5%
Systolic Blood Pressure
5%
Hemoglobin A1c (HbA1c)
5%
CANVAS Program
5%
Empagliflozin
5%
Hypertension
5%
